webinar

Biomarker endpoints for Parkinson’s disease

Supported by:

14 March 2018

Supported by:

14 March 2018

Biomarker endpoints for Parkinson’s disease

ABOUT THIS WEBINAR:

Therapeutic approaches for Parkinson’s disease are either focused on disease modification (a-synuclein or MPTP models) or symptom management (haloperidol or 6-OHDA models). Our scientists have validated available PD models for changes in fine motor skills, L-dopa-induced dyskinesias, drug-induced jaw movements, and non-motor endpoints such as cognition, constipation, and EDS. Additionally, we have also tested dopamine and other neurotransmitter levels in brain compartments of rodent and large animal models via microdialysis sampling.

This webinar provides a comprehensive review of clinically relevant endpoints identified in established and novel animal models of PD that can be used to assess the efficacy of novel disease-modifying and symptom focused therapies.

Send this to a friend